These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28453552)

  • 21. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan.
    Lamming DW; Mihaylova MM; Katajisto P; Baar EL; Yilmaz OH; Hutchins A; Gultekin Y; Gaither R; Sabatini DM
    Aging Cell; 2014 Oct; 13(5):911-7. PubMed ID: 25059582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
    Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
    Zhang X; Wang X; Xu T; Zhong S; Shen Z
    Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTORC1 and JNK coordinate phosphorylation of the p70S6K1 autoinhibitory domain in skeletal muscle following functional overloading.
    Martin TD; Dennis MD; Gordon BS; Kimball SR; Jefferson LS
    Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1397-405. PubMed ID: 24801387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
    Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
    PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
    Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
    Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IKK interacts with rictor and regulates mTORC2.
    Xu Y; Lai E; Liu J; Lin J; Yang C; Jia C; Li Y; Bai X; Li M
    Cell Signal; 2013 Nov; 25(11):2239-45. PubMed ID: 23872070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rictor/mTORC2 pathway in oocytes regulates folliculogenesis, and its inactivation causes premature ovarian failure.
    Chen Z; Kang X; Wang L; Dong H; Wang C; Xiong Z; Zhao W; Jia C; Lin J; Zhang W; Yuan W; Zhong M; Du H; Bai X
    J Biol Chem; 2015 Mar; 290(10):6387-96. PubMed ID: 25564616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
    Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
    Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
    Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
    Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
    Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis.
    Morrison MM; Young CD; Wang S; Sobolik T; Sanchez VM; Hicks DJ; Cook RS; Brantley-Sieders DM
    PLoS Genet; 2015 Jul; 11(7):e1005291. PubMed ID: 26132202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2.
    Boulbes D; Chen CH; Shaikenov T; Agarwal NK; Peterson TR; Addona TA; Keshishian H; Carr SA; Magnuson MA; Sabatini DM; Sarbassov dos D
    Mol Cancer Res; 2010 Jun; 8(6):896-906. PubMed ID: 20501647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A critical role for the mTORC2 pathway in lung fibrosis.
    Chang W; Wei K; Ho L; Berry GJ; Jacobs SS; Chang CH; Rosen GD
    PLoS One; 2014; 9(8):e106155. PubMed ID: 25162417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.
    Wang S; Amato KR; Song W; Youngblood V; Lee K; Boothby M; Brantley-Sieders DM; Chen J
    Mol Cell Biol; 2015 Apr; 35(7):1299-313. PubMed ID: 25582201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.
    Du W; Gerald D; Perruzzi CA; Rodriguez-Waitkus P; Enayati L; Krishnan B; Edmonds J; Hochman ML; Lev DC; Phung TL
    Lab Invest; 2013 Oct; 93(10):1115-27. PubMed ID: 23938603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.